Prof. Cheng Qian 钱诚
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis of breast cancer using molecular and genetic methods. Treatment includes neoadjuvant chemotherapy for locally advanced cases, postoperative individualized chemotherapy, endocrine therapy, breast-conserving surgery, sentinel lymph node biopsy, nerve-sparing procedures, modified radical mastectomy, and minimally invasive surgery for benign tumors.
Dr. Qian holds an MD and PhD from the University of Groningen, Netherlands, where Dr. also completed postdoctoral work and served as a senior scientist. After returning to Harbin Medical University Cancer Hospital in 2012, Dr. Qian completed clinical training at the Seattle Cancer Center in 2016. Dr. Qian is a professor and doctoral supervisor.
Professional roles
- Member, Degree Committee, Heilongjiang Academy of Medical Sciences
- Member, Heilongjiang Stem Cell Association
Name order: in Chinese the family name comes first (Qian Cheng). Papers usually list the name as Cheng Qian or Qian C.
Selected publications
20 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Mol Life Sci, 2026 (senior author): SELENOP-LRP8-mediated macrophage-endothelial cell interaction promotes breast cancer vascular invasion by inducing metabolic reprogramming in endothelial cells. PubMed 42946865
- Front Immunol, 2026 (senior author): An interpretable deep learning framework based on TabNet-Cox for risk stratification and prognostic assessment in hepatocellular carcinoma immunotherapy. PubMed 41756275
- Naunyn Schmiedebergs Arch Pharmacol, 2023 (senior author): Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres. PubMed 37093249
- Toxicol Appl Pharmacol, 2021 (senior author): AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3'-diindolylmethane in human breast cancer cells. PubMed 34464674
- Gland Surg, 2021 (senior author): Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer. PubMed 33968693
- Cell Death Dis, 2020 (senior author): UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop. PubMed 31907353
- Cancer Lett, 2019 (senior author): Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop. PubMed 30771425
- Oncotarget, 2017 (senior author): MiR-23a promotes TGF-β1-induced EMT and tumor metastasis in breast cancer cells by directly targeting CDH1 and activating Wnt/β-catenin signaling. PubMed 29050223
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion